DL-3-n-butylphthalide delays the onset and progression of diabetic cataract by inhibiting oxidative stress in rat diabetic model

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Fuxu ^a   Ma, Jia ^a   Han, Fei ^a   Guo, Xiujin ^a   Meng, Li ^a   Sun, Yufeng ^a   Jin, Cheng ^a   Duan, Huijun ^a   Li, Hang ^a   Peng, Ying ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

3-N-BUTYLPHTHALIDE; BENZOFURAN DERIVATIVE; BIOLOGICAL MARKER; CATALASE; GLUCOSE BLOOD LEVEL; THIOREDOXIN; TRANSCRIPTION FACTOR NRF2; TXN1 PROTEIN, RAT;

ANIMAL; BODY WEIGHT; CATARACT; DIABETIC COMPLICATION; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; LENS; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; RAT;

ANIMALS; BENZOFURANS; BIOMARKERS; BLOOD GLUCOSE; BODY WEIGHT; CATALASE; CATARACT; DIABETES COMPLICATIONS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; IMMUNOHISTOCHEMISTRY; LENS, CRYSTALLINE; MALE; NF-E2-RELATED FACTOR 2; OXIDATIVE STRESS; RATS; THIOREDOXINS;

EID: 84954190544     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep19396     Document Type: Article

References (38)

1. Nirmalan, P. K. et al. Risk factors for age related cataract in a rural population of southern India: the Aravind Comprehensive Eye Study. Br. J. Ophthalmol. 88, 989-994 (2004).
2. Kyselova, Z., Stefek, M. & Bauer, V. Pharmacological prevention of diabetic cataract. J. Diabetes Complications. 18, 129-140 (2004).
3. Nishikawa, T. et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 404, 787-790 (2000).
4. Brownlee, M. Biochemistry and molecular cell biology of diabetic complications. Nature. 414, 813-820 (2001).
5. Zhang, S., Chai, F. Y., Yan, H., Guo, Y. & Harding, J. J. Effects of N-acetylcysteine and glutathione ethyl ester drops on streptozotocin-induced diabetic cataract in rats. Mol. Vis. 14, 862-870 (2008).
6. Kumar, P. A., Reddy, P. Y., Srinivas, P. N. & Reddy, G. B. Delay of diabetic cataract in rats by the antiglycating potential of cumin through modulation of alpha-crystallin chaperone activity. J. Nutr Biochem. 20, 553-562 (2009).
7. Manikandan, R., Thiagarajan, R., Beulaja, S., Sudhandiran, G. & Arumugam, M. Curcumin prevents free radical-mediated cataractogenesis through modulations in lens calcium. Free. Radic. Biol. Med. 48, 483-492 (2010).
8. Itoh, K. et al. Keap1 regulates both cytoplasmic-nuclear shuttling and degradation of Nrf2 in response to electrophiles. Genes. Cells. 8, 379-391 (2003).
9. Gao, P. et al. Nrf2 ameliorates diabetic nephropathy progression by transcriptional repression of TGFβ1 through interactions with c-Jun and SP1. Biochim. Biophys. Acta. 1839, 1110-1120 (2014).
10. Agca, C. A., Tuzcu, M., Hayirl, A. & Sahin K. Taurine ameliorates neuropathy via regulating NF-κB and Nrf2/HO-1 signaling cascades in diabetic rats., Food. Chem. Toxicol. 71, 116-121 (2014).
11. Tan, S. M. et al. Derivative of bardoxolone methyl, dh404, in an inverse dose-dependent manner lessens diabetes-associated atherosclerosis and improves diabetic kidney disease. Diabetes. 63, 3091-3103 (2014).
12. Xiong, N. et al. Dl-3-n-butylphthalide, a natural antioxidant, protects dopamine neurons in rotenone models for Parkinson's disease. Neurobiol. Aging. 33, 1777-1791 (2012).
13. Wang, Y. et al. L-3-n-Butylphthalide protects rats' cardiomyocytes from ischaemia/reperfusion-induced apoptosis by affecting the mitochondrial apoptosis pathway. Acta. Physiol. (Oxf). 210, 524-533 (2014).
14. Feng, X., Peng, Y., Liu, M. & Cui, L. DL-3-n-butylphthalide extends survival by attenuating glial activation in a mouse model of amyotrophic lateral sclerosis. Neuropharmacology. 62, 1004-1010 (2012).
15. Li, J., Zhang, S., Zhang, L., Wang, R. & Wang, M. Effects of L-3-n- Butylphthalide on Cognitive Dysfunction and NR2B Expression in Hippocampus of Streptozotocin (STZ)-Induced Diabetic Rats. Cell. Biochem. Biophys. 71, 315-322 (2015).
16. Oishi, N. et al. Correlation between adult diabetic cataracts and red blood cell aldose reductase levels. Invest. Ophthalmol. Vis. Sci. 47, 2061-2064 (2006).
17. Beebe, D. C., Holekamp, N. M. & Shui, Y. B. Oxidative damage and the prevention of age-related cataracts. Ophthalmic. Res. 44, 155-165 (2010).
18. Porasuphatana, S. et al. Glycemic and oxidative status of patients with type 2 diabetes mellitus following oral administration of alpha-lipoic acid: a randomized double-blinded placebo-controlled study. Asia. Pac. J. Clin. Nutr.21, 12-21 (2012).
19. Swamy-Mruthinti, S., Shaw, S. M., Zhao, H. R., Green, K. & Abraham, E. C. Evidence of a glycemic threshold for the development of cataracts in diabetic rats. Curr. Eye. Res. 18, 423-429 (1999).
20. Agte, V. & Tarwadi, K.,The Importance of Nutrition in the Prevention of Ocular Disease with Special Reference to Cataract. Ophthalmic. Res. 44, 166-172 (2010).
21. Varma, S. D. & Hegde, K. R. Oxidative stress and cataract formation: horizons on its medical prevention. Expert. Rev. Ophthalmol. 2, 779-801 (2007).
22. Grama, C. N. et al. Efficacy of biodegradable curcumin nanoparticles in delaying cataract in diabetic rat model. PLoS. One. 14, e78217 (2013).
23. Zhao, W., Devamanoharan, P. S., Henein, M., Ali, A. H. & Varma, S. D. Diabetes induced biochemical changes in rat lens: attenuation of cataractogenesis by pyruvate. Diabetes. Obes. Metab. 2, 165-174 (2000).
24. Kronschläger, M. et al. Caffeine eye drops protect against UV-B cataract. Exp. Eye. Res. 113, 26-31 (2013).
25. Bahmani, F., Bathaie, S. Z., Aldavood, S. J. & Ghahghaei, A. Glycine therapy inhibits the progression of cataract in streptozotocin-induced diabetic rats. Mol. Vis. 18, 439-448 (2012).
26. Colitz, C. M., Bomser, J. A. & Kusewitt D. F. The endogenous and exogenous mechanisms for protection from ultraviolet irradiation in the lens. Int. Ophthalmol. Clin. 45, 141-155 (2005).
27. Li, H. et al. Attenuation of glomerular injury in diabetic mice with tBHQ through Nrf2-dependent antioxidant gene activation. AM J. NEPHROL. 33, 289-297 (2011).
28. Li, H. et al. Modulation of Nrf2 expression alters high glucose-induced oxidative stress and antioxidant gene expression in mouse mesangial cells. Cellular. Signaling. 23, 1625-1632 (2011).
29. Jiang, T. et al. The protective role of Nrf2 in streptozotocin-induced diabetic nephropathy. Diabetes. 59, 850-860 (2010).
30. Abdo, S. et al. Catalase overexpression prevents nuclear factor erythroid 2-related factor 2 stimulation of renal angiotensinogen gene expression, hypertension, and kidney injury in diabetic mice. Diabetes. 63, 3483-3496 (2014).
31. Santos, M. S. & Moreira, P. I. Insulin therapy modulates mitochondrial dynamics and biogenesis, autophagy and tau protein phosphorylation in the brain of type 1 diabetic rats. Biochim. Biophys. Acta. 1842, 1154-1166 (2014).
32. Miao, X. et al. Zinc protects against diabetes-induced pathogenic changes in the aorta: roles of metallothionein and nuclear factor (erythroid-derived 2)-like 2. Cardiovasc. Diabetol. 12, 54 (2013).
33. Korcsmáros, T. et al. Uniformly curated signaling pathways reveal tissue-specific cross-talks and support drug target discovery. Bioinformatics. 26, 2042-2050 (2010).
34. Truscott, R. J. Age-related nuclear cataract-oxidation is the key. Exp. Eye. Res. 80, 709-725 (2005).
35. Periyasamy, P., Masahiko, A., Rajan, E. & Toshimichi, S. Promoter demethylation of Keap1 gene in human diabetic cataractous lenses. Biochemical And Biophysical Research Communications 423, 542-548 (2012).
36. Wei, M., Xing, K. Y., Fan,Y. C., Libondi, T. & Lou, M. F. Loss of thiol repair systems in human cataractous lenses. Invest. Ophthalmol. Vis. Sci. 56, 598-605 (2014).
37. Zheng, Y. et al. Resveratrol protects human lens epithelial cells against H2O2-induced oxidative stress by increasing Catalase, SOD-1, and HO-1 expression. Mol. Vis. 16, 1467-1474 (2010).
38. Ao, S., Kikuchi, C., Ono, T. & Notsu, Y. Effect of instillation of aldose reductase inhibitor FR74366 on diabetic cataract. Invest. Ophthalmol. Vis. Sci. 32, 3078-3083 (1991).